Ramelteon: a melatonin receptor agonist for the treatment of insomnia.
J Postgrad Med
;
2008 Jan-Mar; 54(1): 45-8
Artículo
en Inglés
| IMSEAR
| ID: sea-115805
ABSTRACT
Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for the treatment of insomnia characterized by difficulty in sleep onset. It is a nonscheduled drug since it lacks the potential for abuse and does not interact with neurotransmitter receptors most associated with these phenomena. Although the effects of ramelteon use > 5 weeks are unknown, the available data confirms its safety and efficacy for short-term use. Clinical use and future research should uncover more information about ramelteon's properties.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Humanos
/
Resultado del Tratamiento
/
Receptores de Melatonina
/
Interacciones Farmacológicas
/
Indenos
/
Trastornos del Inicio y del Mantenimiento del Sueño
Idioma:
Inglés
Revista:
J Postgrad Med
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS